STOCK TITAN

Innate Pharma S.A. (IPHA) Total Assets by Year

IPHA NASDAQ

Innate Pharma S.A. closed fiscal year 2025 with $73.6M in total assets, $99.1M in total liabilities and -$25.5M in shareholder equity. Total assets fell 43.5% in EUR from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters Innate Pharma S.A. has filed alongside them.

FY2025 annual
Total Assets $73.6M
Total Liabilities $99.1M
Total Equity -$25.5M
YoY (EUR) -43.5%
5Y CAGR (EUR) -27.2%
Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD, translated from EUR

Amounts are shown in US dollars, translated from EUR at the rate recorded for each period. Growth rates marked (EUR) are measured in EUR, the currency the company reports in, so a move in the exchange rate does not count as growth.

Annual figures, oldest first. Point at a bar to read its period.

IPHA Balance Sheet by Fiscal Year

Figures are in USD, translated from EUR at the rate recorded for each period. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-F
Total Assets$73.6M-43.5%$115.0M-36.6%$193.8M-12.1%$213.2M-25.5%$302.8M-13.0%$376.0M-23.4%$450.6M-11.0%$516.9M+76.9%$306.6M
Total Liabilities$99.1M-17.4%$105.8M-17.1%$136.4M-15.1%$155.3M-9.3%$181.2M+5.7%$185.2M-17.7%$206.5M-35.3%$325.5M+82.6%$187.0M
Total Equity-$25.5M-345.7%$9.1M-83.0%$57.4M-4.2%$57.9M-49.6%$121.6M-31.1%$190.8M-28.3%$244.1M+30.1%$191.5M+68.1%$119.6M

IPHA Balance Sheet by Quarter

Figures are in USD, translated from EUR at the rate recorded for each period. Each change compares the quarter with the same quarter a year earlier.

MetricQ4'2520-FQ2'256-KQ4'2420-FQ2'246-KQ4'2320-FQ2'236-KQ4'2220-FQ2'226-KQ4'2120-FQ2'216-KQ4'2020-FQ4'1920-F
Total Assets$73.6M-43.5%$109.4M-38.7%$115.0M-36.6%$162.3M-23.9%$193.8M-12.1%$217.4M-29.0%$213.2M-25.5%$293.6M+5.3%$302.8M-13.0%$315.4M$376.0M-23.4%$450.6M-11.0%
Total Liabilities$99.1M-17.4%$103.3M-28.4%$105.8M-17.1%$131.4M-13.1%$136.4M-15.1%$154.2M-14.0%$155.3M-9.3%$171.8M+23.7%$181.2M+5.7%$157.2M$185.2M-17.7%$206.5M-35.3%
Total Equity-$25.5M-345.7%$6.1M-82.1%$9.1M-83.0%$30.8M-50.2%$57.4M-4.2%$63.2M-50.3%$57.9M-49.6%$121.8M-12.9%$121.6M-31.1%$158.2M$190.8M-28.3%$244.1M+30.1%

What total assets means

Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.

More Innate Pharma S.A. financials

Frequently Asked Questions

Innate Pharma S.A. closed fiscal year 2025 with $73.6M in total assets, $99.1M in total liabilities and -$25.5M in shareholder equity.

Innate Pharma S.A. (IPHA) total assets fell by 43.5% year over year in EUR, the currency it reports in. Translated at each year's own exchange rate, it went from $115.0M to $73.6M in fiscal year 2025.

Across the 9 fiscal years this page covers, Innate Pharma S.A. (IPHA) total assets went from $306.6M in fiscal year 2017 to $73.6M in fiscal year 2025.

Innate Pharma S.A. (IPHA) reported $73.6M in total assets in Q4 2025. This represents a decrease of 43.5% in EUR from the same quarter a year earlier.

Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Innate Pharma S.A. (IPHA) reported on that line in every period on record.